Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome

Acute Coronary Syndrome Clinical Trial

— ticagrelor  

Official title:

Evaluation of the Effects and Plasma Concentration of the Potent Platelet Inhibitor Ticagrelor, After Crushed and Non-crushed Intake, After Semi-urgent Coronary Bypass and in Patients After Cardiac Arrest.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02341729
• Other study ID #: AGO/2013/011
• Status: Completed
• Phase: Phase 4
• Start date: March 2015
• Est. completion date: December 2019

Study information

• Verified date: May 2021
• Source: University Hospital, Ghent
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The first aim of the study is to prove that after starting the therapy with crushed tablets, the platelet inhibition will be as expected after starting therapy with intact tablets. Gurbel et al. showed that 100% of the patients on ticagrelor treatment have a decrease from baseline platelet aggregation of >10% 4 hours after last maintenance dose. So the investigators expect that after 3 days of treatment, all of our patients will have a closing time of more than 106seconds.

The investigators will observe two different clinical conditions of Acute Coronary Syndrome. First after semi-urgent coronary artery bypass graft (CABG) surgery, secondly in patients after cardiac arrest.

Both are clinical situations in which crushed tablets are needed to give. The second objective is to determine plasma concentrations of Ticagrelor and AR-C124910XX (active metabolite of ticagrelor) in these two patient populations after receiving 180mg or 90mg start-dose. Determination of plasma concentrations is done after protein precipitation, by using liquid chromatography with mass spectrometry detection. Measurements will be determined before intake (0h) and at 0,5; 1; 2; 4; 8; 24h and at day 4 +4h.7 The first 24h this will be a crushed tablet and 4 hours after the first intake at day 4 of therapy, this will be a non crushed tablet.

Description:

This study is a single-centre, open-label, non-randomised longitudinal study in which the effect of ticagrelor, both crushed and non-crushed will be evaluated in two separate clinical conditions. The plasma concentrations after a crushed intake will be used to determine the maximum plasma concentration and time to achieve this maximum concentration.

50 patients of each condition:

Condition A: patients who received CPR because of cardiac arrest. A gastric tube is inserted. Subjects receive 2 crushed tablets of ticagrelor (180mg) with 10 ml water and a flush of 20 ml water. The first blood sample is taken before administration. The following samples are taken at 30minutes, 1, 2, 4, 8, 12, and 24h. The ninth sample is taken 24 hours after stopping sedation and 4h after administration of ticagrelor with 10 ml water and a flush of 20 ml water via nasogastric tube. The tenth sample is taken 4 days and 4hours after first intake of ticagrelor, this last sample is mostly after a non-crushed intake of ticagrelor (this depends on the neurological condition of the patient). Only the first dose is a loading dose of 180mg, hereafter a normal dose of 90mg is given.

At each blood sampling moment 1 or 2 samples are taken (see also flow chart). At time 0, 2, 4, 8, 12, 24h, 24h after sedation stop and at 4 days and 4hours after first intake of ticagrelor: a Platelet Function Analysis and an Aggreguide aggregometry is done. For each analysis 3,6ml of blood is needed, this makes a total of 28,8ml for the clotting analyses. At time 30min, 1, 2, 4, 8, 24h and 4 days and 4h; 4ml of blood is needed for the plasma concentration measurements, a total of 28ml.

Condition B: Patients in need of semi-urgent coronary bypass surgery, allowing interrupting the administration of ticagrelor 3 days before surgery. A nasogastric tube is inserted during surgery. On intensive care the patients will receive crushed tablets of ticagrelor with 10 ml water and a flush of 20 ml water via gastric tube, the first dose will be a loading dose. The first blood sample is taken just before surgery (weak effect of ticagrelor because administration has stopped 3 days). The following samples are taken at 30minutes, 1, 2, 4, 8, 12, and 24h. The ninth sample is taken 24 hours after stopping sedation and 4h after administration of ticagrelor with 10 ml water and a flush of 20 ml water via nasogastric tube. The tenth sample is taken 4 days and 4hours after first intake of ticagrelor, this last sample is mostly after a non-crushed intake of ticagrelor (this depends on the neurological condition of the patient). Only the first dose is a loading dose of 180mg, hereafter a normal dose of 90mg is given.

At each blood sampling moment 1 or 2 samples are taken (see also flow chart). At time 0, 2, 4, 8, 12, 24h, 24h after sedation stop and at 4 days and 4hours after first intake of ticagrelor: a Platelet Function Analysis and an Aggreguide aggregometry is done. For each analysis 3,6ml of blood is needed, this makes a total of 25,2ml for the clotting analyses. At time 30min, 1, 2, 4, 8, 24h and 4 days and 4h; 4ml of blood is needed for the plasma concentration measurements, a total of 28ml.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject with an acute myocardial infarction with ST elevation

• Subject with an acute myocardial infarction without ST elevation

• Subject with unstable angina (progressive angina during past 2 weeks, negative cardiac markers, Trop T < 0,014µg/l

• First time of taking Brilique

• = 18 years

• Possibility to take a blood sample before administration of Brilique

• Signed Informed Consent, signed by subject or authorized representative, able and willing to provide written informed consent for study participation

Exclusion Criteria:

• Active haemorrhage

• Moderate or severe liver failure with coagulopathy

• Pregnancy and lactation

• A history of an intra cerebral haemorrhage

• Patient is HIV positive and treated with Ritonavir and /or Atazanavir

• Patient treated with vitamin K antagonist or with a new oral anti coagulant

• Hypersensitivity to ticagrelor or any of the excipients

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Crush Injuries
• Syndrome

Intervention

Drug:
• ticagrelor
crushed tablets and non-crushed tablets

Locations

Country	Name	City	State
Belgium	Intensive Care Unit, Ghent University Hospital	Ghent

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Ghent	AstraZeneca

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Platelet Function Analysis (closing time) and Aggreguide aggregometry (clotting analyses)	The first aim of the study is to prove that after starting the therapy with crushed tablets, the platelet inhibition will be as expected after starting therapy with intact tablets.	5 days
Primary	Plasma concentration measurements : plasma concentrations (using liquid chromatography with mass spectrometry detection)	The second objective is to determine plasma concentrations of Ticagrelor and AR-C124910XX in these two patient populations after receiving 180mg or 90mg start-dose.	5 days